Definitive chemoradiation therapy avoids the perioperative and long-term morbidity of esophagectomy and is the standard of care for cervical esophageal cancer. There are significant differences in tumor response to chemoradiation and recurrence patterns between squamous cell cancer and adenocarcinoma of the esophagus. Multimodality therapy for esophageal cancer continues to progress, now with the widespread use of PET scanning and possible active surveillance in patients with complete clinical response to chemoradiation. As drug development and targeted therapy trials continue to expand, our understanding of tumor biology and precision medicine will continue to refine the treatment of esophageal cancer.Esophageal cancer is the eighth most common cancer worldwide, and its incidence has been increasing over the past several decades. Esophagectomy currently is the standard of care for more advanced early esophageal cancer and should be performed at centers of excellence with high volumes, appropriate supportive staff, and multidisciplinary expertise.With advancing endoscopic technology and screening protocols for Barrett disease, more patients are being diagnosed with early-stage esophageal cancer. These early-stage patients may be amendable to endoscopic therapies, such as endomucosal resection and ablation. These therapies may minimize morbidity, but the elevated risk of recurrence cannot be overlooked. This article reports outcomes and recommendations for surveillance and management of recurrent esophageal cancer following endoscopic therapies.Optimal treatment of esophageal cancer is a complex process dependent on many factors, including stage at diagnosis, medical fitness, physician judgment, and expertise. Despite significant advances in understanding of this cancer, survival remains low. Identifying patients with early-stage disease can enhance their outcomes dramatically. On a broader scale, staging is critical in advancing the quality of care delivered to these patients now and in the future. This article is designed to review clinicians' expertise with staging and to elaborate on the nuances frequently encountered when doing so.Barrett esophagus (BE), defined as intestinal metaplasia of the distal esophageal mucosa, typically results from chronic gastroesophageal reflux disease and is the only known precursor of esophageal adenocarcinoma. The standard of care for the management of early esophageal neoplasia in the setting of BE has changed drastically over the past 15 years. Further investigation into diagnostic and therapeutic adjuncts will continue to improve our ability to control or cure BE before its advancement to a life-threatening malignancy.To care and treat patients with esophageal cancer, one must first understand the epidemiology of Barrett's esophagus (BE). BE is defined as the intestinal metaplasia occurring within the esophagus from normal squamous epithelium to abnormal specialized columnar epithelium. BE, while first described by Allison in 1948, was attributed to Norman Barrett in 1950, who reported a case of chronic peptic ulcer in the lower esophagus that was covered by columnar epithelium. Surgical aortic valve replacement (SAVR) for aortic valve stenosis (AS) patients with small aortic root is associated with a higher rate of prosthesis-patient mismatch and suboptimal clinical outcomes. Aortic valve neocuspidisation using xenologous pericardium (xAVNeo) has shown favorable hemodynamic performance. The aim was to compare 6-year clinical outcomes of xAVNeo with SAVR. Between 2003-2018, 412 patients with severe AS and small aortic root received either xAVNeo (N=114) or bioprosthesis (N=298). After propensity matching, the cohort included 222 patients. The primary endpoints were early-, 6-year mortality and freedom from reoperation. Mean follow-up averaged 3.4±3.1 years and was 95% complete. Early mortality was 8.1% for the SAVR group vs 9.9% for the xAVNeo group, OR 1.25 [CI95% 0.51-2.89]. The estimated survival probabilities at 6 years for the SAVR and xAVNeo cohorts were 89.9% and 88.8%, respectively, OR 1.07 [0.49-2.34]. Progressive degeneration of the neo-cusps resulted in mean gradients increase from 6.1±2.3 mmHg to 22.7±11.5 mmHg ( p<0.0001 ); cusp sclerosis was the most common indication for reoperation in the xAVNeo group with a linearised rate of 1.92% vs. 0.26% per patient-year, rate ratio = 7.41 [CI95% 0.95-333.7]. The freedom from reoperation was 84.8% at 6 years, inferior to that of the SAVR group (100%). Early clinical outcome and 6-year survival following xAVNeo and SAVR was comparable. However, xAVNeo using bovine pericardium was associated with a higher rate of structural valve deterioration and inferior freedom from reoperation when compared to SAVR. Early clinical outcome and 6-year survival following xAVNeo and SAVR was comparable. However, xAVNeo using bovine pericardium was associated with a higher rate of structural valve deterioration and inferior freedom from reoperation when compared to SAVR.Benign main bronchial stenosis may cause a potentially life-threatening condition. Airway silicone stenting is an important option of bronchoscopic treatments for patients with main bronchial stenosis. However, stent migration is one of the most frequent complications, which require repeated bronchoscopic interventions. To resolve this issue, we therefore in the report described a novel designed V-shaped silicone stent for the treatment of unilateral main bronchial stenosis. https://www.selleckchem.com/products/pfk15.html This method may be widely applied to clinical practice to prevent stent migration.Unilateral absence of pulmonary artery (UAPA) is a very rare congenital cardiovascular malformation. To the best of our knowledge, chronic thromboembolic pulmonary hypertension has never been reported in adults with UAPA. In this report, we present the case of a 31-year-old woman with UAPA who developed chronic thromboembolic pulmonary hypertension following multiple episodes of pulmonary embolism due to thrombophilia. Pulmonary thromboendarterectomy was performed, and the short-term outcome was satisfactory.Placental site trophoblastic tumour (PSTT), a rare variety of gestational trophoblastic disease (GTD), is traditionally limited to the uterus, found within the placental implantation site where it can lead to arteriovenous malformations. GTDs are known to metastasize to the lungs, of which, choriocarcinomas are the commonest. However, arteriovenous malformations related to such metastatic lesions are extremely rare. The occurrence of spontaneous pneumothorax in pulmonary arteriovenous malformations, under any circumstances, is rarely reported. Herein, we report a rare case of metastatic PSTT, found within pulmonary arteriovenous malformations, uniquely presenting with spontaneous pneumothorax.